Contravir Pharmaceut (CTRV) 3.9500 $CTRV
ContraVir Pharmaceuticals' HBV Compound CMX157 Receives Extended Patent Life
PR Newswire - Wed Feb 04, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that its licensing partner, Chimerix Inc., has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent titled, "Nucleoside Phosphonate Salts." The patent covers composition of matter for CMX157, ContraVir's Phase 2-ready, highly potent analog of the successful antiviral drug tenofovir DF (Viread®), which ContraVir is developing to treat hepatitis B virus (HBV). The new patent extends ContraVir's intellectual property protection for CMX157 to at least 2031.
CMRX: 40.16 (+0.08)
NASDAQ, NYSE, and OTC-listed Companies Webcast Live to Investors: February 5 at VirtualInvestorConferences.com
PR Newswire - Mon Feb 02, 11:45AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
EGLT: 10.60 (+0.58), EVGN: 10.20 (+0.23), CPG.TO: 32.64 (+0.14), CPG: 26.20 (+0.16)
ContraVir to Present at Two Upcoming Investor Conferences
PR Newswire - Mon Feb 02, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it will present at two upcoming investor conferences. ContraVir is scheduled to present live at VirtualInvestorConferences.com, an interactive real-time virtual conference, to be held February 5, 2015, and at the 17th Annual BIO CEO & Investor Conference, to be held February 9-10, 2015 in New York, NY.
ContraVir Pharmaceuticals elects Dr Carol L. Brosgart to SAB
M2 - Wed Jan 21, 4:39AM CST
Biopharmaceutical company ContraVir Pharmaceuticals (OTCBB:CTRV) disclosed on Tuesday that it has appointed Dr Carol L. Brosgart, MD to its Scientific Advisory Board (SAB) to support the development of its targeted antiviral therapies, including CMX157.
ContraVir Pharmaceuticals Adds Carol L. Brosgart, M.D., to Scientific Advisory Board
PR Newswire - Tue Jan 20, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the addition of Carol L. Brosgart, M.D., to the Company's Scientific Advisory Board (SAB) to support the development of its targeted antiviral therapies, including CMX157, a highly potent analog of the antiviral drug tenofovir, which ContraVir plans to develop for HBV. Dr. Brosgart has a strong background and expertise in viral infectious diseases, particularly hepatology.
ContraVir to Present at Noble Financial Conference
PR Newswire - Thu Jan 15, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the Noble Financial Capital Markets' Eleventh Annual Equity Conference, to be held January 18-21, 2015, in Sandpiper Bay, FL.
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals names Dr John Sullivan-Bolyai as CMO
M2 - Wed Jan 14, 7:04AM CST
Biopharmaceutical company ContraVir Pharmaceuticals (OTCBB:CTRV) revealed on Tuesday the addition of Dr John Sullivan-Bolyai, MD, MPH as its chief medical officer.
MRK: 58.81 (-0.07)
ContraVir Pharmaceuticals Appoints John Sullivan-Bolyai, M.D., MPH, as Chief Medical Officer
PR Newswire - Tue Jan 13, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the appointment of John Sullivan-Bolyai, M.D., MPH, as the Company's Chief Medical Officer.
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals names Dr Renu Gupta to SAB
M2 - Fri Jan 09, 5:49AM CST
Biopharmaceutical company ContraVir Pharmaceuticals (OTCBB:CTRV) disclosed on Thursday the addition of Dr Renu Gupta, MD to its new scientific advisory board.
ContraVir Pharmaceuticals adds Renu Gupta, M.D., to Scientific Advisory Board
PR Newswire - Thu Jan 08, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the addition of Renu Gupta, M.D., to the Company's Scientific Advisory Board (SAB), formed in December 2014, to support the development of its targeted antiviral therapies including their lead antiviral product candidate, FV-100, the primary value driver for ContraVir.
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals to conduct Type B meeting with the US FDA to discuss Phase 3 trial of its lead antiviral candidate FV-100 for treating shingles
M2 - Thu Jan 08, 4:43AM CST
Biopharmaceutical company ContraVir Pharmaceuticals (OTCBB:CTRV) reported on Wednesday that it plans to hold a Type B meeting with the US Food and Drug Administration (FDA) to discuss its proposal for the design of a Phase 3 trial of its lead antiviral candidate, FV-100.
ContraVir Pharmaceuticals Granted FDA Meeting to Discuss Proposal for Phase 3 Trial of FV-100
PR Newswire - Wed Jan 07, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has been granted a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss its proposal for the design of a Phase 3 trial of ContraVir's lead antiviral candidate, FV-100. The meeting will take place in the first quarter of 2015 and will focus on evaluating both completed and planned FV-100 clinical studies, including the proposed upcoming Phase 3 trial of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals to Present at Biotech Showcase 2015
PR Newswire - Tue Jan 06, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the Company is scheduled to present at the Biotech Showcase(TM) 2015 taking place in San Francisco, CA on January 12-14, 2015.
SGYP: 2.98 (unch)
Chimerix and ContraVir team up in antiviral development
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 9:23AM CST
CMRX: 40.16 (+0.08), GILD: 101.90 (+1.10)
Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug Candidate CMX157
PR Newswire Europe - Thu Dec 18, 5:00AM CST
-- ContraVir to develop CMX157 for multiple antiviral indications --
SGYP: 2.98 (unch), CMRX: 40.16 (+0.08)
ContraVir Pharmaceuticals Appoints Nathaniel Katz, M.D., Chairman of New Scientific Advisory Board
PR Newswire - Tue Dec 16, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the formation of a Scientific Advisory Board (SAB) to support the development of the Company's targeted antiviral therapies. The Company also announced that Nathaniel Katz, M.D., global expert in post herpetic neuralgia (PHN) pain management and President and Chief Executive Officer of Analgesic Solutions, a research, education, and consulting firm focused exclusively on pain therapeutics, has joined ContraVir as Chairman of the newly formed SAB.
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals' HBV Compound CMX157 Receives Extended Patent Life
PR Newswire - Wed Feb 04, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that its licensing partner, Chimerix Inc., has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent titled, "Nucleoside Phosphonate Salts." The patent covers composition of matter for CMX157, ContraVir's Phase 2-ready, highly potent analog of the successful antiviral drug tenofovir DF (Viread®), which ContraVir is developing to treat hepatitis B virus (HBV). The new patent extends ContraVir's intellectual property protection for CMX157 to at least 2031.
CMRX: 40.16 (+0.08)
NASDAQ, NYSE, and OTC-listed Companies Webcast Live to Investors: February 5 at VirtualInvestorConferences.com
PR Newswire - Mon Feb 02, 11:45AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
EGLT: 10.60 (+0.58), EVGN: 10.20 (+0.23), CPG.TO: 32.64 (+0.14), CPG: 26.20 (+0.16)
ContraVir to Present at Two Upcoming Investor Conferences
PR Newswire - Mon Feb 02, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it will present at two upcoming investor conferences. ContraVir is scheduled to present live at VirtualInvestorConferences.com, an interactive real-time virtual conference, to be held February 5, 2015, and at the 17th Annual BIO CEO & Investor Conference, to be held February 9-10, 2015 in New York, NY.
ContraVir Pharmaceuticals elects Dr Carol L. Brosgart to SAB
M2 - Wed Jan 21, 4:39AM CST
Biopharmaceutical company ContraVir Pharmaceuticals (OTCBB:CTRV) disclosed on Tuesday that it has appointed Dr Carol L. Brosgart, MD to its Scientific Advisory Board (SAB) to support the development of its targeted antiviral therapies, including CMX157.
ContraVir Pharmaceuticals Adds Carol L. Brosgart, M.D., to Scientific Advisory Board
PR Newswire - Tue Jan 20, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the addition of Carol L. Brosgart, M.D., to the Company's Scientific Advisory Board (SAB) to support the development of its targeted antiviral therapies, including CMX157, a highly potent analog of the antiviral drug tenofovir, which ContraVir plans to develop for HBV. Dr. Brosgart has a strong background and expertise in viral infectious diseases, particularly hepatology.
ContraVir to Present at Noble Financial Conference
PR Newswire - Thu Jan 15, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the Noble Financial Capital Markets' Eleventh Annual Equity Conference, to be held January 18-21, 2015, in Sandpiper Bay, FL.
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals names Dr John Sullivan-Bolyai as CMO
M2 - Wed Jan 14, 7:04AM CST
Biopharmaceutical company ContraVir Pharmaceuticals (OTCBB:CTRV) revealed on Tuesday the addition of Dr John Sullivan-Bolyai, MD, MPH as its chief medical officer.
MRK: 58.81 (-0.07)
ContraVir Pharmaceuticals Appoints John Sullivan-Bolyai, M.D., MPH, as Chief Medical Officer
PR Newswire - Tue Jan 13, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the appointment of John Sullivan-Bolyai, M.D., MPH, as the Company's Chief Medical Officer.
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals names Dr Renu Gupta to SAB
M2 - Fri Jan 09, 5:49AM CST
Biopharmaceutical company ContraVir Pharmaceuticals (OTCBB:CTRV) disclosed on Thursday the addition of Dr Renu Gupta, MD to its new scientific advisory board.
ContraVir Pharmaceuticals adds Renu Gupta, M.D., to Scientific Advisory Board
PR Newswire - Thu Jan 08, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the addition of Renu Gupta, M.D., to the Company's Scientific Advisory Board (SAB), formed in December 2014, to support the development of its targeted antiviral therapies including their lead antiviral product candidate, FV-100, the primary value driver for ContraVir.
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals to conduct Type B meeting with the US FDA to discuss Phase 3 trial of its lead antiviral candidate FV-100 for treating shingles
M2 - Thu Jan 08, 4:43AM CST
Biopharmaceutical company ContraVir Pharmaceuticals (OTCBB:CTRV) reported on Wednesday that it plans to hold a Type B meeting with the US Food and Drug Administration (FDA) to discuss its proposal for the design of a Phase 3 trial of its lead antiviral candidate, FV-100.
ContraVir Pharmaceuticals Granted FDA Meeting to Discuss Proposal for Phase 3 Trial of FV-100
PR Newswire - Wed Jan 07, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has been granted a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss its proposal for the design of a Phase 3 trial of ContraVir's lead antiviral candidate, FV-100. The meeting will take place in the first quarter of 2015 and will focus on evaluating both completed and planned FV-100 clinical studies, including the proposed upcoming Phase 3 trial of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals to Present at Biotech Showcase 2015
PR Newswire - Tue Jan 06, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the Company is scheduled to present at the Biotech Showcase(TM) 2015 taking place in San Francisco, CA on January 12-14, 2015.
SGYP: 2.98 (unch)
Chimerix and ContraVir team up in antiviral development
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 9:23AM CST
CMRX: 40.16 (+0.08), GILD: 101.90 (+1.10)
Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug Candidate CMX157
PR Newswire Europe - Thu Dec 18, 5:00AM CST
-- ContraVir to develop CMX157 for multiple antiviral indications --
SGYP: 2.98 (unch), CMRX: 40.16 (+0.08)
ContraVir Pharmaceuticals Appoints Nathaniel Katz, M.D., Chairman of New Scientific Advisory Board
PR Newswire - Tue Dec 16, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the formation of a Scientific Advisory Board (SAB) to support the development of the Company's targeted antiviral therapies. The Company also announced that Nathaniel Katz, M.D., global expert in post herpetic neuralgia (PHN) pain management and President and Chief Executive Officer of Analgesic Solutions, a research, education, and consulting firm focused exclusively on pain therapeutics, has joined ContraVir as Chairman of the newly formed SAB.
SGYP: 2.98 (unch)
